As a common primary tumour, gel tumours originate in rubber cells, and in neurosurgery treatment of gel tumours has been a priority and a challenge.
At present, integrated treatments such as chemotherapy are combined, mainly for surgical removal and mainly for glyphosmosis. The objective of the surgical removal is to remove the tumour tissue as far as possible, to reduce the internal pressure of the skull, to reduce the symptoms of the patient and to create favourable conditions for follow-up treatment.
However, because of immersive growth, boundaries are often difficult to define clearly, posing a great challenge to the complete removal of tumours, whose development prospects are now very serious. During the operation, neurosurgeons, with sophisticated technology and advanced neuronn-navigation systems, endeavour to protect the normal brain tissue and nervous functions around them while maximizing tumour removal.
The role of therapeutic treatment in the treatment of glaucoma cannot be overlooked. The growth and growth of tumour cells can be inhibited by high-energy ray exposure to tumour areas. However, there are a number of side effects such as the potential for radio-brain damage, loss of cognitive function, etc., and there is a need to develop an accurate programme to balance the effects of the treatment with the adverse effects. Oncular cells are often treated chemically by chemotherapy, such as mothamine, which produces cytotoxic effects through blood and brain barriers. However, tumour cells may have an impact on the effects of chemotherapy, as tumour cells become resistant when the treatment is long.
In recent years, there have been some new developments in the treatment of gel tumours in the context of in-depth medical research. Immunization treatment is a hot spot for research. The human immune system is capable of identifying and removing tumour cells, but through a variety of mechanisms, the tumour cells can escape immune monitoring.
Immunotherapy is an immunotherapy method that activates its own immune system or increases the lethality of immunocellular cells on tumour cells. For example, immunosuppressants can disrupt the functioning of proteins on the tumour cell surface at the immunoscopy point and re-activate the immune cell as an attack on the tumour. There are also some oncological vaccines that are being developed to prevent and treat glucoma by stimulating specific immune responses to the organism. Targeting treatment is also a promising direction.
A growing number of tumour-specific molecular targets have been found as a result of the continued knowledge of the molecular biological mechanisms of the glaucoma. Drugs for these targets can work more precisely so that tumour cells are not damaged by normal cells. Targeting drugs that target certain gene mutations or unusual signal paths can interrupt the transmission of tumour cell growth signals and induce tumour cells to collapse.
In addition, genetic therapy is being explored. Treatment is achieved through the import of normal genes from external sources or the correction of abnormal genes from tumour cells. For example, cancer-free genes are imported into gelatinous cells, using viruses to inhibit the growth and development of tumours. Although there has been much exploration and progress in the treatment of gelatinoma, overall, especially at high levels, the prognosis of gelatinoma is less positive. The quality and duration of a patient ‘ s survival require further improvement.
In the future, further in-depth research is needed on the mechanisms for the development of glyphosmics, the excavation of more effective treatment targets and the development of new treatment drugs and technologies. At the same time, the best individualized treatment for patients, the multidisciplinary collaborative treatment model (MDT) will also play a more critical role in the treatment of gelatinoma, with the participation of multidisciplinary specialists such as neurosurgery, discharge, chemotherapy and pathology. It is believed that, as medical technology continues to develop, the problem of geloma will eventually be overcome, giving hope to many patients.
Neoplasm
